HC Wainwright Predicts Reduced Earnings for DBV Technologies

Posted by George Bondi on Jul 21st, 2026

DBV Technologies S.A. (NASDAQ:DBVT – Free Report) – HC Wainwright lowered their FY2027 EPS estimates for DBV Technologies in a research report issued on Friday, July 17th. HC Wainwright analyst A. Fein now anticipates that the company will earn ($1.45) per share for the year, down from their previous forecast of ($1.05). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for DBV Technologies’ FY2028 earnings at $1.15 EPS, FY2029 earnings at $3.85 EPS and FY2030 earnings at $6.65 EPS.

A number of other research firms have also recently issued reports on DBVT. Citizens Jmp raised their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 30th. Wall Street Zen lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a report on Saturday, July 4th. Weiss Ratings downgraded DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. Citigroup restated an “outperform” rating on shares of DBV Technologies in a research note on Friday, May 1st. Finally, Guggenheim reaffirmed a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a research report on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, DBV Technologies currently has an average rating of “Moderate Buy” and a consensus price target of $48.50.

Check Out Our Latest Research Report on DBV Technologies

DBV Technologies Trading Down 0.9%

NASDAQ:DBVT opened at $14.57 on Tuesday. DBV Technologies has a twelve month low of $8.51 and a twelve month high of $26.18. The company has a market cap of $862.69 million, a PE ratio of -4.15 and a beta of -0.95. The company’s 50 day moving average is $17.02 and its two-hundred day moving average is $19.45.

DBV Technologies (NASDAQ:DBVT – Get Free Report) last announced its quarterly earnings data on Thursday, July 16th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.48). The company had revenue of $0.70 million during the quarter, compared to analysts’ expectations of $0.90 million. DBV Technologies had a negative net margin of 3,506.53% and a negative return on equity of 119.33%.

Institutional Trading of DBV Technologies

Several institutional investors and hedge funds have recently bought and sold shares of DBVT. Perceptive Advisors LLC acquired a new stake in DBV Technologies during the 1st quarter valued at approximately $20,146,000. Vivo Capital LLC increased its stake in shares of DBV Technologies by 8.4% in the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after acquiring an additional 205,943 shares during the period. ADAR1 Capital Management LLC acquired a new stake in shares of DBV Technologies in the first quarter worth $21,159,000. Royal Bank of Canada raised its holdings in shares of DBV Technologies by 167.1% during the first quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock worth $98,000 after purchasing an additional 2,928 shares during the last quarter. Finally, Elmind Capital LP purchased a new position in shares of DBV Technologies during the first quarter worth $5,536,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.

DBV Technologies Company Profile

(Get Free Report)

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.